Exact Mass: 339.25352100000003

Exact Mass Matches: 339.25352100000003

Found 203 metabolites which its exact mass value is equals to given mass value 339.25352100000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

evocarpine

(Z)-1-Methyl-2-(tridec-8-en-1-yl)quinolin-4(1H)-one

C23H33NO (339.25620080000004)


Evocarpine is a member of quinolines. Evocarpine is a natural product found in Tetradium ruticarpum with data available. 1-methyl-2-[(E)-tridec-8-enyl]quinolin-4-one is a natural product found in Tetradium ruticarpum with data available. Evocarpine, a quinolone alkaloid that could be isolated from Evodiae fructus, inhibitss Ca2+ influx through voltage-dependent calcium channels. Antimycobacterial activity[1][2]. Evocarpine, a quinolone alkaloid that could be isolated from Evodiae fructus, inhibitss Ca2+ influx through voltage-dependent calcium channels. Antimycobacterial activity[1][2].

   

Propoxyphene

(3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate

C22H29NO2 (339.2198174)


Propoxyphene is only found in individuals that have used or taken this drug. It is a narcotic analgesic structurally related to methadone. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect. [PubChem]Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Disopyramide

alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide

C21H29N3O (339.2310504)


A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. [PubChem] C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BA - Antiarrhythmics, class ia D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

noracymethadol

Paracymethadol hydrochloride, (r*,r*)-(+-)-isomer

C22H29NO2 (339.2198174)


noracymethadol is a metabolite of levomethadyl acetate. Levacetylmethadol, levomethadyl acetate (USAN), Orlaam (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites. (Wikipedia) D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   
   

4-(3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol

4-(3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol

C22H29NO2 (339.2198174)


   

Oleoyl glycine

2-[(9Z)-octadec-9-enamido]acetic acid

C20H37NO3 (339.27732920000005)


N-oleoyl glycine is an acylglycine with oleoic acid (C18:1(9Z))moiety attached to glycine molecule. It is reported to be preferentially produced by human glycine N-acyltransferase-like 2 (hGLYATL2), a member of a gene family of 4 putative glycine conjugating enzymes, synthesizes various N-acyl glycines. Recombinantly expressed hGLYATL2 efficiently conjugated oleoyl-CoA, arachidonoyl-CoA, and other medium- and long-chain acyl-CoAs to glycine. The enzyme was specific for glycine as an acceptor molecule. N-oleoyl glycine is an acylglycine with oleoic acid (C18:1(9Z))moiety attached to glycine molecule N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte. N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.

   

(7Z,9E)-Dodeca-7,9-dienoylcarnitine

3-(dodeca-7,9-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


(7Z,9E)-Dodeca-7,9-dienoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,9E)-dodeca-7,9-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,9E)-Dodeca-7,9-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (7Z,9E)-Dodeca-7,9-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E,7E)-Dodeca-5,7-dienoylcarnitine

3-(dodeca-5,7-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


(5E,7E)-Dodeca-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (5E,7E)-dodeca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E,7E)-Dodeca-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5E,7E)-Dodeca-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,8Z)-Dodeca-2,8-dienoylcarnitine

3-(Dodeca-2,8-dienoyloxy)-4-(trimethylazaniumyl)butanoic acid

C19H33NO4 (339.2409458000001)


(2E,8Z)-Dodeca-2,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,8Z)-dodeca-2,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,8Z)-Dodeca-2,8-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,8Z)-Dodeca-2,8-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,4E)-Dodeca-2,4-dienoylcarnitine

3-(dodeca-2,4-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


(2E,4E)-Dodeca-2,4-dienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E)-dodeca-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E)-Dodeca-2,4-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4E)-Dodeca-2,4-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,6Z)-Dodeca-2,6-dienoylcarnitine

3-(dodeca-2,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


(2E,6Z)-Dodeca-2,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,6Z)-dodeca-2,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6Z)-Dodeca-2,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6Z)-Dodeca-2,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8Z,10E)-Dodeca-8,10-dienoylcarnitine

3-(dodeca-8,10-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


(8Z,10E)-Dodeca-8,10-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,10E)-dodeca-8,10-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,10E)-Dodeca-8,10-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (8Z,10E)-Dodeca-8,10-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Oleoyl Glycine

N-[(4-Fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboximidate

C20H37NO3 (339.27732920000005)


N-oleoyl glycine, also known as MK-0518, raltegravirum, or isentress belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Blonanserin C

1-[4-(4-fluorophenyl)-5H,6H,7H,8H,9H,10H-cycloocta[b]pyridin-2-yl]piperazine

C21H26FN3 (339.21106480000003)


   

3b-Hydroxy-17-(1h-1,2,3-triazol-1-yl)androsta-5,16-diene

2,15-dimethyl-14-(1H-1,2,3-triazol-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-ol

C21H29N3O (339.2310504)


   

(Z)-1-Methyl-2-(tridec-8-en-1-yl)quinolin-4(1H)-one

1-methyl-2-(tridec-8-en-1-yl)-1,4-dihydroquinolin-4-one

C23H33NO (339.25620080000004)


   

l-Propoxyphene

4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate

C22H29NO2 (339.2198174)


   

4-[(1R,2S)-3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol

4-[(1R,2S)-3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol

C22H29NO2 (339.2198174)


   
   
   

(Z)-1-Methyl-2-(tridec-7-enyl)quinolin-4-one

(Z)-1-Methyl-2-(tridec-7-enyl)quinolin-4-one

C23H33NO (339.25620080000004)


   

1-Methyl-2-[(4Z)-tridec-4-enyl]quinolin-4-one

1-Methyl-2-[(4Z)-tridec-4-enyl]quinolin-4-one

C23H33NO (339.25620080000004)


   

tumonoic acid A

(-)-Tumonoic acid A

C19H33NO4 (339.2409458000001)


A natural product found particularly in Oscillatoria margaritifera and Oscillatoria margaritifera.

   

(1-((Tetrahydro-2H-pyran-4-yl)methyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

(1-((Tetrahydro-2H-pyran-4-yl)methyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

C22H29NO2 (339.2198174)


   
   
   
   
   

2-acetamido-3-acetoxyhexadec-15-ene|diacetyl obscuraminol F

2-acetamido-3-acetoxyhexadec-15-ene|diacetyl obscuraminol F

C20H37NO3 (339.27732920000005)


   

(9Z)-2-acetamido-3-acetoxyhexadec-9-ene|diacetyl obscuraminol D

(9Z)-2-acetamido-3-acetoxyhexadec-9-ene|diacetyl obscuraminol D

C20H37NO3 (339.27732920000005)


   
   

9-O-(erythro-2-hydroxy-2-methyl-3-tigloyloxy-butyryl)-(-)-trachelanthamidine|minalobine O

9-O-(erythro-2-hydroxy-2-methyl-3-tigloyloxy-butyryl)-(-)-trachelanthamidine|minalobine O

C18H29NO5 (339.20456240000004)


   

1,8,15-triazacyclohenicosane-2,9,16-trione

1,8,15-triazacyclohenicosane-2,9,16-trione

C18H33N3O3 (339.2521788)


   

1-[1]Naphthyl-cyclopentancarbonsaeure-(2-diaethylamino-aethylester)|1-[1]naphthyl-cyclopentanecarboxylic acid-(2-diethylamino-ethyl ester)

1-[1]Naphthyl-cyclopentancarbonsaeure-(2-diaethylamino-aethylester)|1-[1]naphthyl-cyclopentanecarboxylic acid-(2-diethylamino-ethyl ester)

C22H29NO2 (339.2198174)


   

dioxo-3,18 conadiene-1,4

dioxo-3,18 conadiene-1,4

C22H29NO2 (339.2198174)


   
   

(2E,4Z)-4-amino-2,3-dimethylheptadeca-2,4-diene-dioic acid|nemopilemic acid

(2E,4Z)-4-amino-2,3-dimethylheptadeca-2,4-diene-dioic acid|nemopilemic acid

C19H33NO4 (339.2409458000001)


   

SCHEMBL11594344

SCHEMBL11594344

C24H37N (339.2925842)


   

oxo-3 hydroxy-18alpha conatriene-1,4,14

oxo-3 hydroxy-18alpha conatriene-1,4,14

C22H29NO2 (339.2198174)


   

N-Hexadecanoyl-(S)-3-Aminodihydro-2-furanone

N-Hexadecanoyl-(S)-3-Aminodihydro-2-furanone

C20H37NO3 (339.27732920000005)


   

6beta-Isovaleryloxy-3alpha-tigloyloxy-tropanol-(7beta)

6beta-Isovaleryloxy-3alpha-tigloyloxy-tropanol-(7beta)

C18H29NO5 (339.20456240000004)


   

(11Z)-2-acetamido-3-acetoxyhexadec-11-ene|diacetyl obscuraminol E

(11Z)-2-acetamido-3-acetoxyhexadec-11-ene|diacetyl obscuraminol E

C20H37NO3 (339.27732920000005)


   

N-(1,2-Dioxotetradecyl)-2-methylene-beta-alanine methyl ester

N-(1,2-Dioxotetradecyl)-2-methylene-beta-alanine methyl ester

C19H33NO4 (339.2409458000001)


   

2,4-Diphenylbutyric acid 2-(diethylamino)ethyl ester

2,4-Diphenylbutyric acid 2-(diethylamino)ethyl ester

C22H29NO2 (339.2198174)


   
   

methyl 2-amino-3-(3,7,11-trimethyldodeca-2,6,10-trienylsulfanyl)propanoate

methyl 2-amino-3-(3,7,11-trimethyldodeca-2,6,10-trienylsulfanyl)propanoate

C19H33NO2S (339.22318780000006)


   

N-Hexadecanoyl-DL-homoserine lactone

N-Hexadecanoyl-DL-homoserine lactone

C20H37NO3 (339.27732920000005)


   

(+)-7-epi-12-hydroxyjasmonoyl-L-isoleucine

(+)-7-epi-12-hydroxyjasmonoyl-L-isoleucine

C18H29NO5 (339.20456240000004)


   
   

Propoxyphene

dextropropoxyphene

C22H29NO2 (339.2198174)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; EAWAG_UCHEM_ID 3344

   

disopyramide

disopyramide

C21H29N3O (339.2310504)


C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BA - Antiarrhythmics, class ia D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Vincadifformine

Vincadifformine

[C21H27N2O2]+ (339.2072422)


Origin: Plant; SubCategory_DNP: Monoterpenoid indole alkaloids, Aspidosperma alkaloids, Indole alkaloids

   
   

(7R,8R,E)-6-((2R,E)-6,7-dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol

(7R,8R,E)-6-((2R,E)-6,7-dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol

C19H33NO4 (339.2409458000001)


   

N-(5Z,8Z,11Z,14Z-eicosatetrayoyl)-ethanolamine

N-(5Z,8Z,11Z,14Z-eicosatetrayoyl)-ethanolamine

C22H29NO2 (339.2198174)


   
   

N-hexadecanoyl-L-Homoserine lactone

N-[(3S)-tetrahydro-2-oxo-3-furanyl]-hexadecanamide

C20H37NO3 (339.27732920000005)


   

EMA-1

N-(9Z-octadecenoyl)-glycine

C20H37NO3 (339.27732920000005)


N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte. N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.

   

cis-5,8,11,14-eicosatetraynoyl ethanolamide

cis-5,8,11,14-eicosatetraynoyl ethanolamide

C22H29NO2 (339.2198174)


   

CAR 12:2

3-[(2E,5Z)-dodeca-2,5-dienoyloxy]-4-(trimethylazaniumyl)butanoate

C19H33NO4 (339.2409458000001)


   

C16-HSL

N-(hexadecanoyl)-homoserine lactone

C20H37NO3 (339.27732920000005)


   

NAE 20:8

cis-5,8,11,14-eicosatetraynoyl ethanolamide

C22H29NO2 (339.2198174)


   

13-HODE-EA

N-(13-hydroxy-9Z,11E-octadecadienoyl)-ethanolamine

C20H37NO3 (339.27732920000005)


   

13-NAE-HOD

N-(13S-hydroxy-9Z,11E-octadecadienoyl)-ethanolamine

C20H37NO3 (339.27732920000005)


   

NAE-9-HOD

N-(9S-hydroxy-10E,12Z-octadecadienoyl)-ethanolamine

C20H37NO3 (339.27732920000005)


   

Rociverine

1-(Diethylamino)-2-propanyl (1R,2R)-1-hydroxy-1,1-bi(cyclohexyl) -2-carboxylate

C20H37NO3 (339.27732920000005)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   
   

N-METHYLSARPAGINE METHOSALT

N-METHYLSARPAGINE METHOSALT

C21H27N2O2+ (339.2072422)


   

Uracil,6-amino-5-(2-dibutylaminoacetamido)-1,3-dimethyl- (6CI)

Uracil,6-amino-5-(2-dibutylaminoacetamido)-1,3-dimethyl- (6CI)

C16H29N5O3 (339.2270284)


   

4-(diethylamino) (2-dodecenyl)-4-oxo-Butanoic acid

4-(diethylamino) (2-dodecenyl)-4-oxo-Butanoic acid

C20H37NO3 (339.27732920000005)


   

Tetrabutylammonium hydrogensulfate

Tetrabutylammonium hydrogensulfate

C16H37NO4S (339.2443162)


   

levopropoxyphene

levopropoxyphene

C22H29NO2 (339.2198174)


C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

   

1-Dodecanaminium, N,N,N-trimethyl-, methyl sulfate

1-Dodecanaminium, N,N,N-trimethyl-, methyl sulfate

C16H37NO4S (339.2443162)


   

N-[dimethylamino-ethylimino-[[tris(dimethylamino)-λ5-phosphanylidene]amino]-λ5-phosphanyl]-N-methylmethanamine

N-[dimethylamino-ethylimino-[[tris(dimethylamino)-λ5-phosphanylidene]amino]-λ5-phosphanyl]-N-methylmethanamine

C12H35N7P2 (339.242905)


   

Benzododecinium chloride

Lauryl benzalkonium chloride

C21H38ClN (339.26926180000004)


D013501 - Surface-Active Agents > D003902 - Detergents > D001548 - Benzalkonium Compounds C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents D004202 - Disinfectants

   
   

6-N-Benzylamino-1-(4-phenylbutoxy)Hexane

6-N-Benzylamino-1-(4-phenylbutoxy)Hexane

C23H33NO (339.25620080000004)


   

2-(Dicyclohexylphosphino)-1-phenyl-1H-pyrrole

2-(Dicyclohexylphosphino)-1-phenyl-1H-pyrrole

C22H30NP (339.21157500000004)


   

cetylpyridinium chloride

cetylpyridinium chloride

C21H38ClN (339.26926180000004)


COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D001697 - Biomedical and Dental Materials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   
   

ammonium hexadecyl sulphate

ammonium hexadecyl sulphate

C16H37NO4S (339.2443162)


   

Tetrabutylammonium phosphate monobasic

Tetrabutylammonium phosphate monobasic

C16H38NO4P (339.2538318)


   
   

4-[(1R,2S)-3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol

4-[(1R,2S)-3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol

C22H29NO2 (339.2198174)


   

Propoxyphene, (R,R)-

Propoxyphene, (R,R)-

C22H29NO2 (339.2198174)


   

2-[6-(2-Hydroxy-2-phenyl-ethyl)-1-methyl-2-piperidyl]-1-phenyl-ethanol

2-[6-(2-Hydroxy-2-phenyl-ethyl)-1-methyl-2-piperidyl]-1-phenyl-ethanol

C22H29NO2 (339.2198174)


   

N-[(3S)-Tetrahydro-2-oxo-3-furanyl]hexadecanamide

N-[(3S)-Tetrahydro-2-oxo-3-furanyl]hexadecanamide

C20H37NO3 (339.27732920000005)


   

3alpha-hydroxy-3,5-dihydromonacolin L carboxylate

3alpha-hydroxy-3,5-dihydromonacolin L carboxylate

C19H31O5- (339.2171376)


A hydroxy monocarboxylic acid anion that is the conjugate base of 3alpha-hydroxy-3,5-dihydromonacolin L acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-({(1R,2S)-2-[(2Z)-5-hydroxypent-2-en-1-yl]-3-oxocyclopentyl}acetyl)-L-isoleucine

N-({(1R,2S)-2-[(2Z)-5-hydroxypent-2-en-1-yl]-3-oxocyclopentyl}acetyl)-L-isoleucine

C18H29NO5 (339.20456240000004)


   

methyl (1S,12R,19S)-12-ethyl-8-aza-16-azoniapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate

methyl (1S,12R,19S)-12-ethyl-8-aza-16-azoniapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate

C21H27N2O2+ (339.2072422)


   

3b-Hydroxy-17-(1h-1,2,3-triazol-1-yl)androsta-5,16-diene

3b-Hydroxy-17-(1h-1,2,3-triazol-1-yl)androsta-5,16-diene

C21H29N3O (339.2310504)


   

(7Z,9E)-Dodeca-7,9-dienoylcarnitine

(7Z,9E)-Dodeca-7,9-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

(5E,7E)-Dodeca-5,7-dienoylcarnitine

(5E,7E)-Dodeca-5,7-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

(2E,8Z)-Dodeca-2,8-dienoylcarnitine

(2E,8Z)-Dodeca-2,8-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

(2E,4E)-Dodeca-2,4-dienoylcarnitine

(2E,4E)-Dodeca-2,4-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

(2E,6Z)-Dodeca-2,6-dienoylcarnitine

(2E,6Z)-Dodeca-2,6-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

(8Z,10E)-Dodeca-8,10-dienoylcarnitine

(8Z,10E)-Dodeca-8,10-dienoylcarnitine

C19H33NO4 (339.2409458000001)


   

Noracymethadol, (-)-

Noracymethadol, (-)-

C22H29NO2 (339.2198174)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   
   

(+)-Vincadifformine(1+)

(+)-Vincadifformine(1+)

C21H27N2O2+ (339.2072422)


An ammonium ion resulting from the protonation of the tertiary amino group of (+)-vincadifformine. The major species at pH 7.3.

   

(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(15S)-hydroperoxy-(11Z,13E)-eicosadienoate

(15S)-hydroperoxy-(11Z,13E)-eicosadienoate

C20H35O4- (339.25352100000003)


   

(5S)-hydroperoxy-(6E,8Z)-eicosadienoate

(5S)-hydroperoxy-(6E,8Z)-eicosadienoate

C20H35O4- (339.25352100000003)


   

Secodine(1+)

Secodine(1+)

C21H27N2O2+ (339.2072422)


A tertiary ammonium ion that is the conjugate acid of secodine, obtained by protonation of the nitrogen atom of the tetrahydropyridine moiety. The major microspecies at pH 7.3.

   
   

(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C16H29N5O3 (339.2270284)


   

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

(1R,5S)-N-cyclohexyl-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

(1R,5S)-N-cyclohexyl-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

C21H29N3O (339.2310504)


   

(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-(methylaminomethyl)-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C16H29N5O3 (339.2270284)


   

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-propan-2-ylurea

C17H29N3O4 (339.21579540000005)


   

(1S,5R)-N-cyclohexyl-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1S,5R)-N-cyclohexyl-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C21H29N3O (339.2310504)


   

1-[(1S,5R)-7-[4-(1-cyclohexenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-(dimethylamino)ethanone

1-[(1S,5R)-7-[4-(1-cyclohexenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-(dimethylamino)ethanone

C21H29N3O (339.2310504)


   

(Z,Z)-dicyclopropyl-methoxymycolate

(Z,Z)-dicyclopropyl-methoxymycolate

C20H35O4- (339.25352100000003)


   

N-({(1R)-2-[(2Z)-5-hydroxypent-2-en-1-yl]-3-oxocyclopentyl}acetyl)-L-isoleucine

N-({(1R)-2-[(2Z)-5-hydroxypent-2-en-1-yl]-3-oxocyclopentyl}acetyl)-L-isoleucine

C18H29NO5 (339.20456240000004)


   

(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoic acid

(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoic acid

C19H33NO4 (339.2409458000001)


   

10,11-epoxy-12-hydroxy-(14Z)-eicosenoate

10,11-epoxy-12-hydroxy-(14Z)-eicosenoate

C20H35O4- (339.25352100000003)


   

12-hydroperoxy-(10E,14Z)-eicosadienoate

12-hydroperoxy-(10E,14Z)-eicosadienoate

C20H35O4- (339.25352100000003)


   

14,15-epoxy-12-hydroxy-(10E)-eicosenoate

14,15-epoxy-12-hydroxy-(10E)-eicosenoate

C20H35O4- (339.25352100000003)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octanamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexanamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]propanamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]acetamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentanamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]butanamide

C20H37NO3 (339.27732920000005)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptanamide

C20H37NO3 (339.27732920000005)


   

2-(2-Amino-2-methylpropyl)-1-methyl-3-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydro-4-pyridyl)indole

2-(2-Amino-2-methylpropyl)-1-methyl-3-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydro-4-pyridyl)indole

C22H33N3 (339.26743380000005)


   

2-(2-Amino-2-methylpropyl)-3-(1,2,2,6,6-pentamethyl-1,2,3,6-tetrahydro-4-pyridyl)indole

2-(2-Amino-2-methylpropyl)-3-(1,2,2,6,6-pentamethyl-1,2,3,6-tetrahydro-4-pyridyl)indole

C22H33N3 (339.26743380000005)


   

methyl (19S)-12-ethyl-16-aza-8-azoniapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,9-tetraene-10-carboxylate

methyl (19S)-12-ethyl-16-aza-8-azoniapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,9-tetraene-10-carboxylate

C21H27N2O2+ (339.2072422)


   

N-Oleoylglycine

N-Oleoylglycine

C20H37NO3 (339.27732920000005)


A fatty acid derivative that is the 9Z-octadecenoyl derivative of glycine. It is believed to be an intermediate in oleamide biosynthesis. N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte. N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.

   

NORACYMETHADOL

NORACYMETHADOL

C22H29NO2 (339.2198174)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   
   

Nor-laam

L-alpha-Acetyl-N-normethadol

C22H29NO2 (339.2198174)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

(-)-vincadifformine(1+)

(-)-vincadifformine(1+)

C21H27N2O2 (339.2072422)


An ammonium ion resulting from the protonation of the tertiary amino group of (-)-vincadifformine. The major species at pH 7.3.

   

(-)-coronaridine(1+)

(-)-coronaridine(1+)

C21H27N2O2 (339.2072422)


An ammonium ion derivative resulting from the protonation of the tertiary amino group of (-)-coronaridine.

   

N-[(+)-12-hydroxy-7-isojasmonyl]isoleucine

N-[(+)-12-hydroxy-7-isojasmonyl]isoleucine

C18H29NO5 (339.20456240000004)


An L-isoleucine derivative resulting from the formal condensation of the carboxy group of (+)-12-hydroxy-7-isojasmonic acid with the amino group of L-isoleucine.

   
   
   
   
   
   
   

n-[(2s,3r)-3-(acetyloxy)hexadec-15-en-2-yl]ethanimidic acid

n-[(2s,3r)-3-(acetyloxy)hexadec-15-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

1-methyl-2-[(8e)-tridec-8-en-1-yl]quinolin-4-one

1-methyl-2-[(8e)-tridec-8-en-1-yl]quinolin-4-one

C23H33NO (339.25620080000004)


   

(1s,3r,5r,6r,7s)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

(1s,3r,5r,6r,7s)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

1-methyl-2-[(z)-7-teidecenyl]-4-(1h)-quinolone

NA

C23H33NO (339.25620080000004)


{"Ingredient_id": "HBIN002761","Ingredient_name": "1-methyl-2-[(z)-7-teidecenyl]-4-(1h)-quinolone","Alias": "NA","Ingredient_formula": "C23H33NO","Ingredient_Smile": "CCCCCC=CCCCCCCC1=CC(=O)C2=CC=CC=C2N1C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "31674","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

1-methyl-2-[(z)-7-tridecenyl]-4(1h)-quinolone

NA

C23H33NO (339.25620080000004)


{"Ingredient_id": "HBIN002762","Ingredient_name": "1-methyl-2-[(z)-7-tridecenyl]-4(1h)-quinolone","Alias": "NA","Ingredient_formula": "C23H33NO","Ingredient_Smile": "CCCCCC=CCCCCCCC1=CC(=O)C2=CC=CC=C2N1C","Ingredient_weight": "339.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT16714","TCMID_id": "14733","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5319779","DrugBank_id": "NA"}

   

n-[3-(acetyloxy)hexadec-15-en-2-yl]ethanimidic acid

n-[3-(acetyloxy)hexadec-15-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

(2s,13s,15r,16r,19r,20r,21r)-21-hydroxy-1,11,19-trimethyl-18-oxa-1,11-diazahexacyclo[11.8.0.0²,¹⁶.0⁴,¹².0⁵,¹⁰.0¹⁵,²⁰]henicosa-4(12),5,7,9-tetraen-1-ium

(2s,13s,15r,16r,19r,20r,21r)-21-hydroxy-1,11,19-trimethyl-18-oxa-1,11-diazahexacyclo[11.8.0.0²,¹⁶.0⁴,¹².0⁵,¹⁰.0¹⁵,²⁰]henicosa-4(12),5,7,9-tetraen-1-ium

[C21H27N2O2]+ (339.2072422)


   

n-[(2s,3r,9z)-3-(acetyloxy)hexadec-9-en-2-yl]ethanimidic acid

n-[(2s,3r,9z)-3-(acetyloxy)hexadec-9-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

2-{[(1r,2s,4r,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.0¹,⁵]undec-5-en-4-yl]amino}benzoic acid

2-{[(1r,2s,4r,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.0¹,⁵]undec-5-en-4-yl]amino}benzoic acid

C22H29NO2 (339.2198174)


   

(3r,5r,6r)-3-amino-n-(2-carbamimidoylethyl)-5-hydroxy-6-{[(2e,4z)-1-hydroxyhexa-2,4-dien-1-ylidene]amino}heptanimidic acid

(3r,5r,6r)-3-amino-n-(2-carbamimidoylethyl)-5-hydroxy-6-{[(2e,4z)-1-hydroxyhexa-2,4-dien-1-ylidene]amino}heptanimidic acid

C16H29N5O3 (339.2270284)


   

n-[3-(acetyloxy)hexadec-9-en-2-yl]ethanimidic acid

n-[3-(acetyloxy)hexadec-9-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

1,13,17,17-tetramethyl-9-azapentacyclo[10.8.0.0²,¹⁰.0³,⁸.0¹³,¹⁸]icosa-3,5,7-trien-16-ol

1,13,17,17-tetramethyl-9-azapentacyclo[10.8.0.0²,¹⁰.0³,⁸.0¹³,¹⁸]icosa-3,5,7-trien-16-ol

C23H33NO (339.25620080000004)


   

(2e,4z)-4-amino-2,3-dimethylheptadeca-2,4-dienedioic acid

(2e,4z)-4-amino-2,3-dimethylheptadeca-2,4-dienedioic acid

C19H33NO4 (339.2409458000001)


   

(2e,4e,8e,10z,14z)-n-(2-methylbutyl)octadeca-2,4,8,10,14-pentaen-12-ynimidic acid

(2e,4e,8e,10z,14z)-n-(2-methylbutyl)octadeca-2,4,8,10,14-pentaen-12-ynimidic acid

C23H33NO (339.25620080000004)


   

1-[(3-methoxy-4-methylidene-1,5-dihydropyrrol-2-yl)sulfanyl]tridecan-1-one

1-[(3-methoxy-4-methylidene-1,5-dihydropyrrol-2-yl)sulfanyl]tridecan-1-one

C19H33NO2S (339.22318780000006)


   

(1r,2s,10s,12s,13r,16r,18r)-1,13,17,17-tetramethyl-9-azapentacyclo[10.8.0.0²,¹⁰.0³,⁸.0¹³,¹⁸]icosa-3,5,7-trien-16-ol

(1r,2s,10s,12s,13r,16r,18r)-1,13,17,17-tetramethyl-9-azapentacyclo[10.8.0.0²,¹⁰.0³,⁸.0¹³,¹⁸]icosa-3,5,7-trien-16-ol

C23H33NO (339.25620080000004)


   

n-[3-(acetyloxy)hexadec-11-en-2-yl]ethanimidic acid

n-[3-(acetyloxy)hexadec-11-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

3-[2-(1h-indol-3-ylmethyl)-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propan-1-ol

3-[2-(1h-indol-3-ylmethyl)-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propan-1-ol

C23H33NO (339.25620080000004)


   

(1s)-2-[(2s,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanol

(1s)-2-[(2s,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanol

C22H29NO2 (339.2198174)


   

n-[(2s,3r,11z)-3-(acetyloxy)hexadec-11-en-2-yl]ethanimidic acid

n-[(2s,3r,11z)-3-(acetyloxy)hexadec-11-en-2-yl]ethanimidic acid

C20H37NO3 (339.27732920000005)


   

(3r,5r,6r)-3-amino-n-(2-carbamimidoylethyl)-5-hydroxy-6-{[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]amino}heptanimidic acid

(3r,5r,6r)-3-amino-n-(2-carbamimidoylethyl)-5-hydroxy-6-{[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]amino}heptanimidic acid

C16H29N5O3 (339.2270284)


   

(2r,3s)-4-[(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethoxy]-3-hydroxy-3-methyl-4-oxobutan-2-yl (2e)-2-methylbut-2-enoate

(2r,3s)-4-[(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethoxy]-3-hydroxy-3-methyl-4-oxobutan-2-yl (2e)-2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

2-({2,6,7,7-tetramethyltricyclo[6.2.1.0¹,⁵]undec-5-en-4-yl}amino)benzoic acid

2-({2,6,7,7-tetramethyltricyclo[6.2.1.0¹,⁵]undec-5-en-4-yl}amino)benzoic acid

C22H29NO2 (339.2198174)


   

(3r)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

(3r)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylbut-2-enoate

6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

(3s)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

(3s)-6-hydroxy-8-methyl-7-[(3-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

(2r,3r,6r)-2-methyl-6-(11-oxododecyl)piperidin-3-yl acetate

(2r,3r,6r)-2-methyl-6-(11-oxododecyl)piperidin-3-yl acetate

C20H37NO3 (339.27732920000005)


   

(4z)-4-amino-2,3-dimethylheptadeca-2,4-dienedioic acid

(4z)-4-amino-2,3-dimethylheptadeca-2,4-dienedioic acid

C19H33NO4 (339.2409458000001)


   

(1s)-2-[(2s,6r)-6-[(2r)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanol

(1s)-2-[(2s,6r)-6-[(2r)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanol

C22H29NO2 (339.2198174)


   

1-(3-hydroxy-2,4-dimethyldodec-4-enoyl)pyrrolidine-2-carboxylic acid

1-(3-hydroxy-2,4-dimethyldodec-4-enoyl)pyrrolidine-2-carboxylic acid

C19H33NO4 (339.2409458000001)


   

2-methyl-6-(11-oxododecyl)piperidin-3-yl acetate

2-methyl-6-(11-oxododecyl)piperidin-3-yl acetate

C20H37NO3 (339.27732920000005)


   

4-(hexahydro-1h-pyrrolizin-1-ylmethoxy)-3-hydroxy-3-methyl-4-oxobutan-2-yl 2-methylbut-2-enoate

4-(hexahydro-1h-pyrrolizin-1-ylmethoxy)-3-hydroxy-3-methyl-4-oxobutan-2-yl 2-methylbut-2-enoate

C18H29NO5 (339.20456240000004)


   

4-ethylidene-7,12-dihydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecan-8-one

4-ethylidene-7,12-dihydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecan-8-one

C18H29NO5 (339.20456240000004)


   

(1r,4e,6r,7r,11s,12s,17r)-4-ethylidene-7,12-dihydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecan-8-one

(1r,4e,6r,7r,11s,12s,17r)-4-ethylidene-7,12-dihydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecan-8-one

C18H29NO5 (339.20456240000004)


   

(2s)-1-[(2r,4e)-3-hydroxy-2,4-dimethyldodec-4-enoyl]pyrrolidine-2-carboxylic acid

(2s)-1-[(2r,4e)-3-hydroxy-2,4-dimethyldodec-4-enoyl]pyrrolidine-2-carboxylic acid

C19H33NO4 (339.2409458000001)


   

3-[(1s,2r,3r)-2-(1h-indol-3-ylmethyl)-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propan-1-ol

3-[(1s,2r,3r)-2-(1h-indol-3-ylmethyl)-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propan-1-ol

C23H33NO (339.25620080000004)